Prostate cancer is the most commonly diagnosed cancer in men and affects millions of people. In recent years both the detection and incidence have increased dramatically. The natural history of prostate cancer is enigmatic leading to significant controversies concerning screening tests and proper therapeutic management. The only established systemic therapy for this disease focuses on androgen ablation. Androgen deprivation induces programmed cell death in hormone-dependent prostatic cancer. However, androgen-independent cells are present early in the evolution of prostate cancer and virtually all patients eventually develop androgen-independent tumor, a serious clinical problem for which no effective therapy exists. The mechanisms of development and biochemical pathways that contribute to androgen-independent growth are unknown. Existing classifications of prostate cancer offer little information regarding prognosis or predicted response to therapy for individual patients. Molecular profiles that distinguish androgen-dependent from androgen-independent prostate cancer will provide insight into the critical pathways that regulate tumor growth and response to therapy, and can be used for classification with regard to hormone sensitivity. The overall goal of our research program is to characterize the molecular events underlying the clinical features of prostate cancer and provide a basis for molecular classification and targeted therapy. Comprehensive analyses of a human prostate cancer xenograft have demonstrated that expression levels in large numbers of genes change dramatically in the course of selection for androgen-independent growth. Androgen-independent tumors have a distinct molecular profile resulting from altered expression of many genes, some of which are known to play a role in the androgen signal transduction pathway, but many are of unknown function. Based on this encouraging result we expect that androgen-independent primary human prostate cancer will have a distinct molecular profile. We propose 1) to define molecular profiles that are representative of androgen-independent prostate carcinoma by comprehensive, microarray-based gene expression analysis and comparison of androgen-dependent and androgen independent tumors, 2) to develop robust molecular histopathologic methods to identify and quantitate androgen-dependent and -independent tumor cell subclones within primary human prostate carcinomas for molecular classification of individual tumors, and 3) to analyze the relationship between molecular classification and clinical course of disease in statistically sound retrospective and prospective studies. These studies will provide the basis for an in-depth understanding of the role of androgens in prostate cancer, mechanisms for development of hormone refractory disease and the clinical utility of a molecular classification based on this information.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA084999-04
Application #
6514357
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (M1))
Program Officer
Lively, Tracy (LUGO)
Project Start
1999-09-30
Project End
2004-03-31
Budget Start
2002-04-10
Budget End
2003-03-31
Support Year
4
Fiscal Year
2002
Total Cost
$927,687
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Zhang, Liying; Altuwaijri, Saleh; Deng, Fangming et al. (2009) NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175:489-99
Chitale, D; Gong, Y; Taylor, B S et al. (2009) An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28:2773-83
Narla, Goutham; DiFeo, Analisa; Fernandez, Yolanda et al. (2008) KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 118:2711-21
Ouyang, Xuesong; Jessen, Walter J; Al-Ahmadie, Hikmat et al. (2008) Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 68:2132-44
Motoi, Noriko; Szoke, Janos; Riely, Gregory J et al. (2008) Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32:810-27
Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma; Shedden, Kerby; Taylor, Jeremy M G et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:822-7
Bean, James; Brennan, Cameron; Shih, Jin-Yuan et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-7
Gao, Hui; Ouyang, Xuesong; Banach-Petrosky, Whitney A et al. (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103:14477-82
Ryan, Charles J; Smith, Alex; Lal, Priti et al. (2006) Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 68:834-9
Stephenson, Andrew J; Smith, Alex; Kattan, Michael W et al. (2005) Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104:290-8

Showing the most recent 10 out of 17 publications